A new data portal called Cancer-Immu established by a team of Vanderbilt University Medical Center biostatisticians can help cancer clinicians and researchers predict which patients will respond to immune checkpoint inhibitors. With data from 3,652 samples for 16 cancer types, Cancer-Immu is the largest immune checkpoint blockade-related data portal for exploring immunogenomic connections.The team provided details about the open-access portal in a paper published Dec. 13 in&n .